Literature DB >> 1389517

Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.

J Steinberg1, C Erlichman, T Gadalla, S Fine, A Wong.   

Abstract

We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer. Now we have analysed prognostic factors for response, toxicity, survival and time to progression. The variables used for survival and response were treatment centre, treatment, age, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), site of disease, previous radiotherapy, site of primary, disease-free interval, initial alkaline phosphatase (AP), albumin (A), lactate dehydrogenase (LDH) and aspartate aminotransferase (SGOT). The significant independent variables for survival were PS of 2 or more, initial albumin and SGOT, and treatment received, in order of importance. The relative risk of death when patients received 5-FU/folinic acid was 60% of that of patients receiving 5-FU alone. The variables predictive of response were treatment and PS. The variables used for analysis of toxicity were age, treatment centre, treatment, sex, tumour response, PS, number of courses, SGOT, AP and albumin. Treatment was found to be predictive of toxicity. Thus, baseline albumin and SGOT, and 5-FU/folinic acid treatment are significant determinants of survival, 5-FU/folinic acid and PS of 2 or more are major determinants of response and no clinical parameter could be identified as a predictor of toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389517     DOI: 10.1016/0959-8049(92)90011-p

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

2.  Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer.

Authors:  Laura A Healy; Aoife M Ryan; Ellis Sutton; Katherine Younger; Brain Mehigan; Richard Stephens; John V Reynolds
Journal:  Int J Colorectal Dis       Date:  2010-06-20       Impact factor: 2.571

3.  Completion of therapy by Medicare patients with stage III colon cancer.

Authors:  Sharon A Dobie; Laura-Mae Baldwin; Jason A Dominitz; Barbara Matthews; Kevin Billingsley; William Barlow
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

4.  Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.

Authors:  N C Tebbutt; A R Norman; D Cunningham; M E Hill; D Tait; J Oates; S Livingston; J Andreyev
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

5.  Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer.

Authors:  Katsuya Makihara; Rino Fukui; Hitomi Uchiyama; Yasushi Shigeoka; Akihiro Toyokawa
Journal:  J Gastrointest Oncol       Date:  2019-10

6.  Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.

Authors:  L Assersohn; A Norman; D Cunningham; T Benepal; P J Ross; J Oates
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer.

Authors:  Masayuki Shibata; Masaru Fukahori; Eiji Kasamatsu; Koji Machii; Satoshi Hamauchi
Journal:  Adv Ther       Date:  2020-10-16       Impact factor: 3.845

8.  Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy.

Authors:  Ioannis D Xynos; Nicolaos Kavantzas; Smaro Tsaousi; Michalis Zacharakis; George Agrogiannis; Christos Kosmas; Andreas Lazaris; John Sarantonis; Stavros Sougioultzis; Dimitrios Tzivras; Aris Polyzos; Efstratios S Patsouris; Nikolas Tsavaris
Journal:  ISRN Gastroenterol       Date:  2013-06-04

9.  Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer.

Authors:  Tetsuro Tominaga; Takashi Nonaka; Yorihisa Sumida; Shigekazu Hidaka; Terumitsu Sawai; Takeshi Nagayasu
Journal:  World J Surg Oncol       Date:  2016-07-28       Impact factor: 2.754

10.  Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).

Authors:  N Marschner; M Frank; W Vach; E Ladda; A Karcher; S Winter; M Jänicke; T Trarbach
Journal:  Colorectal Dis       Date:  2019-03-18       Impact factor: 3.788

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.